Sphera Funds Management’s Alpine Immune Sciences Inc ALPN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-44,841
Closed -$1.78M 138
2024
Q1
$1.78M Sell
44,841
-190,000
-81% -$5.61M 0.25% 82
2023
Q4
$4.48M Buy
234,841
+54,841
+30% +$762K 0.72% 53
2023
Q3
$2.06M Sell
180,000
-20,000
-10% -$246K 0.38% 66
2023
Q2
$2.06M Hold
200,000
0.32% 71
2023
Q1
$1.54M Hold
200,000
0.26% 64
2022
Q4
$1.47M Hold
200,000
0.32% 47
2022
Q3
$1.44M Buy
+200,000
New +$1.65M 0.2% 58
2021
Q2
Sell
-198,260
Closed -$2.1M 174
2021
Q1
$2.1M Hold
198,260
0.16% 108
2020
Q4
$2.5M Hold
198,260
0.22% 82
2020
Q3
$1.74M Buy
+198,260
New +$1.81M 0.17% 79
2016
Q4
Sell
-51,175
Closed -$1.66M 121
2016
Q3
$1.66M Buy
+51,175
New +$1.25M 0.27% 80
2016
Q2
Sell
-19,975
Closed -$333K 114
2016
Q1
$333K Sell
19,975
-37,912
-65% -$759K 0.07% 86
2015
Q4
$1.79M Buy
57,887
+7,457
+15% +$255K 0.26% 91
2015
Q3
$2.62M Sell
50,430
-13,320
-21% -$875K 0.33% 73
2015
Q2
$3.86M Buy
+63,750
New +$3.8M 0.38% 63

Sphera Funds Management's ALPN Position: Q2 2024 in Review

Sphera Funds Management sold out of Alpine Immune Sciences Inc (ALPN) in Q2 2024, closing a stake of 44,841 shares — an estimated $1.78M sold.

Sphera Funds Management first reported a position in ALPN in Q2 2015 and held it in 15 quarters. The position peaked at $4.48M in Q4 2023. 0 funds tracked by Wall St. Rank hold ALPN as of Q2 2024.

  • Sphera Funds Management reported no remaining Alpine Immune Sciences Inc position as of Q2 2024 after selling out during the quarter.
  • Sphera Funds Management sold 44,841 Alpine Immune Sciences Inc shares in Q2 2024, an estimated $1.78M.
  • Sphera Funds Management first reported a position in Alpine Immune Sciences Inc in Q2 2015 and held it in 15 quarters.
  • Sphera Funds Management's Alpine Immune Sciences Inc position peaked at $4.48M in Q4 2023.
  • 0 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q2 2024.

Based on Sphera Funds Management's 13F filing for Q2 2024, filed 14 Aug 2024.